Skip to main content

anitocabtagene autoleucel

anitocabtagene autoleucel: 1 clinical trial tracked.

anitocabtagene autoleucel evidence translation

What we can confirm

1 tracked trial

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about anitocabtagene autoleucel, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trials (1)

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma

NCT06413498·Phase 3
Active, not recruiting

Primary endpoint: Progression-Free Survival (PFS)

InterventionalRandomizedopen452 enrolledStarted 2024-08Completion 2031-0750 sites · Australia, United StatesKite, A Gilead Company